Evidence map›Paper›PMID 33839288›Full record

ReviewMethods (San Diego, Calif.)2022

CRISPR-Cas systems for diagnosing infectious diseases.

Anastasiya Kostyusheva, Sergey Brezgin, Yurii Babin, Irina Vasilyeva, Dieter Glebe, Dmitry Kostyushev, Vladimir Chulanov

Abstract readReview
In one paragraph

Review in Methods (San Diego, Calif.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. CRISPR-Cas12a diagnostics forAnnals of medicine and surgery (2012) · 2026
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anastasiya KostyushevaNational Medical Research Center of Tuberculosis and Infectious Diseases, Ministry of Health, Moscow, Russia. Electronic address: kostyusheva_ap@mail.ru.
Sergey BrezginNational Medical Research Center of Tuberculosis and Infectious Diseases, Ministry of Health, Moscow, Russia; Institute of Immunology, Moscow, Russia.
Yurii BabinNational Medical Research Center of Tuberculosis and Infectious Diseases, Ministry of Health, Moscow, Russia.
Irina VasilyevaNational Medical Research Center of Tuberculosis and Infectious Diseases, Ministry of Health, Moscow, Russia.
Dieter GlebeInstitute of Medical Virology, University of Giessen, Giessen, Germany.
Dmitry KostyushevNational Medical Research Center of Tuberculosis and Infectious Diseases, Ministry of Health, Moscow, Russia; Sirius University of Science and Technology, Sochi, Russia.
Vladimir ChulanovNational Medical Research Center of Tuberculosis and Infectious Diseases, Ministry of Health, Moscow, Russia; Sechenov University, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infectious diseases are a global health problem affecting billions of people. Developing rapid and sensitive diagnostic tools is key for successful patient management and curbing disease spread. Currently available diagnostics are very specific and sensitive but time-consuming and require expensive laboratory settings and well-trained personnel; thus, they are not available in resource-limited areas, for the purposes of large-scale screenings and in case of outbreaks and epidemics. Developing new, rapid, and affordable point-of-care diagnostic assays is urgently needed. This review focuses on CRISPR-based technologies and their perspectives to become platforms for point-of-care nucleic acid detection methods and as deployable diagnostic platforms that could help to identify and curb outbreaks and emerging epidemics. We describe the mechanisms and function of different classes and types of CRISPR-Cas systems, including pros and cons for developing molecular diagnostic tests and applications of each type to detect a wide range of infectious agents. Many Cas proteins (Cas3, Cas9, Cas12, Cas13, Cas14 etc.) have been leveraged to create highly accurate and sensitive diagnostic tools combined with technologies of signal amplification and fluorescent, potentiometric, colorimetric, lateral flow assay detection and other. In particular, the most advanced platforms -- SHERLOCK/v2, DETECTR, CARMEN or CRISPR-Chip -- enable detection of attomolar amounts of pathogenic nucleic acids with specificity comparable to that of PCR but with minimal technical settings. Further developing CRISPR-based diagnostic tools promises to dramatically transform molecular diagnostics, making them easily affordable and accessible virtually anywhere in the world. The burden of socially significant diseases, frequent outbreaks, recent epidemics (MERS, SARS and the ongoing COVID-19) and outbreaks of zoonotic viruses (African Swine Fever Virus etc.) urgently need the developing and distribution of express-diagnostic tools. Recently devised CRISPR-technologies represent the unprecedented opportunity to reshape epidemiological surveillance and molecular diagnostics.

Indexed as

African Swine Fever VirusCommunicable DiseasesCOVID-19AnimalsCRISPR-Cas SystemsHumansNucleic Acid Amplification TechniquesPoint-of-Care SystemsSwineCOVID-19HBVHIVHPVMobile phone microscopyMolecular diagnosticsMolecular epidemiologyOne pot assaysPoint-of-care (POC)SARS-CoV-2TuberculosisViruses

Identifiers

PMID33839288
PMCPMC8032595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.